Correlation Between Acrivon Therapeutics, and Puma Biotechnology

Can any of the company-specific risk be diversified away by investing in both Acrivon Therapeutics, and Puma Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Acrivon Therapeutics, and Puma Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Acrivon Therapeutics, Common and Puma Biotechnology, you can compare the effects of market volatilities on Acrivon Therapeutics, and Puma Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Acrivon Therapeutics, with a short position of Puma Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Acrivon Therapeutics, and Puma Biotechnology.

Diversification Opportunities for Acrivon Therapeutics, and Puma Biotechnology

-0.05

Correlation Coefficient

Acrivon Therapeutics,  Puma Biotechnology

Good diversification

The 3 months correlation between Acrivon and Puma is -0.05. Overlapping area represents the amount of risk that can be diversified away by holding Acrivon Therapeutics, Common and Puma Biotechnology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Puma Biotechnology and Acrivon Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Acrivon Therapeutics, Common are associated (or correlated) with Puma Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Puma Biotechnology has no effect on the direction of Acrivon Therapeutics, i.e., Acrivon Therapeutics, and Puma Biotechnology go up and down completely randomly.

Pair Corralation between Acrivon Therapeutics, and Puma Biotechnology

Given the investment horizon of 90 days Acrivon Therapeutics, Common is expected to under-perform the Puma Biotechnology. But the stock apears to be less risky and, when comparing its historical volatility, Acrivon Therapeutics, Common is 1.15 times less risky than Puma Biotechnology. The stock trades about -0.08 of its potential returns per unit of risk. The Puma Biotechnology is currently generating about -0.01 of returns per unit of risk over similar time horizon. If you would invest  321.00  in Puma Biotechnology on September 13, 2024 and sell it today you would lose (19.00) from holding Puma Biotechnology or give up 5.92% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Acrivon Therapeutics, Common  vs.  Puma Biotechnology

Acrivon Therapeutics,

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Acrivon Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in January 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

Puma Biotechnology

Risk-Adjusted Performance

6 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Puma Biotechnology are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite fairly unsteady basic indicators, Puma Biotechnology demonstrated solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Acrivon Therapeutics, and Puma Biotechnology

The main advantage of trading using opposite Acrivon Therapeutics, and Puma Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Acrivon Therapeutics, position performs unexpectedly, Puma Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Puma Biotechnology will offset losses from the drop in Puma Biotechnology's long position.

The idea behind Acrivon Therapeutics, Common and Puma Biotechnology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.